SIGI Stock Analysis: Selective Insurance | NASDAQ
Insurance - Property & Casualty | NASDAQ, USA | Market Cap: 5.996m USD | 12M Return: 12.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.1M
EPS Trend: 35.0%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Selective Insurance Group, Inc. (SIGI) is a U.S.-based insurance holding company that provides property, casualty, and flood insurance products through four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. The company distributes its products via independent retail agents and wholesale general agents, serving businesses, non-profit organizations, local government agencies, and individuals. Founded in 1926 and headquartered in Branchville, New Jersey, Selective has been publicly traded on NASDAQ since 1990 and operates in the Property & Casualty Insurance sub-industry. The P&C insurance sector is typically driven by underwriting discipline, premium pricing cycles, and investment income from policyholder premiums, with carriers often earning returns from both underwriting profits and investment portfolios of fixed income securities, equities, and alternative assets. Excess & Surplus (E&S) Lines, one of SIGIs segments, cover risks that standard insurers decline, often commanding higher premiums in specialized or hard-to-place markets.
- E&S Lines premium growth outpaces standard commercial segment
- Net investment income expands as portfolio yields rise with higher rates
- Catastrophe losses pressure combined ratio in storm-heavy quarters
| Net Income: 454.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.05 > 1.0 |
| NWC/Revenue: 18.34% < 20% (prev -16.35%; Δ 34.69% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.17b > Net Income 454.2m |
| Net Debt (-95.0m) to EBITDA (846.6m): -0.11 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.5m) vs 12m ago -1.31% < -2% |
| Gross Margin: 41.56% > 18% (prev 28.53%; Δ 13.03% > 0.5%) |
| Asset Turnover: 38.11% > 50% (prev 38.21%; Δ -0.11% > 0%) |
| Interest Coverage Ratio: 10.73 > 6 (EBIT TTM 567.9m / Interest Expense TTM 52.9m) |
| A: 0.06 (Total Current Assets 3.86b - Total Current Liabilities 2.87b) / Total Assets 15.3b |
| B: 0.23 (Retained Earnings 3.57b / Total Assets 15.3b) |
| C: 0.04 (EBIT TTM 567.9m / Avg Total Assets 14.2b) |
| D: 0.31 (Book Value of Equity 3.59b / Total Liabilities 11.7b) |
| Altman-Z'' = 1.77 = BBB |
| DSRI: 1.55 (Receivables 2.58b/1.54b, Revenue 5.40b/4.98b) |
| GMI: 0.69 (GM 28.53% / 41.56%) |
| AQI: 0.86 (AQ_t 0.74 / AQ_t-1 0.87) |
| SGI: 1.08 (Revenue 5.40b / 4.98b) |
| TATA: -0.05 (NI 454.2m - CFO 1.17b) / TA 15.3b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of July 10, 2026, the stock is trading at USD 95.53 with a total of 661,857 shares traded. Over the past week, the price has changed by -2.54%, over one month by +5.85%, over three months by +17.69% and over the past year by +12.92%.
Current recommended Stop Loss: 92.40 (which is 3.3% or 1.4 ATR below the current price).
Selective Insurance has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold SIGI.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.4 | -3.2% |
P/E Trailing = 13.7004
P/E Forward = 11.7647
P/S = 1.0846
P/B = 1.7148
P/EG = 0.2766
Revenue TTM = 5.40b USD
EBIT TTM = 567.9m USD
EBITDA TTM = 846.6m USD
Long Term Debt = 898.5m USD (from longTermDebt, last quarter)
Short Term Debt = 13.1m USD (from shortTermDebt, last fiscal year)
Debt = 904.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.90m
Net Debt = -95.0m USD (calculated: Debt 904.3m - CCE 999.3m)
Enterprise Value = 5.90b USD (6.00b + Debt 904.3m - CCE 999.3m)
Interest Coverage Ratio = 10.73 (Ebit TTM 567.9m / Interest Expense TTM 52.9m)
EV/FCF = 5.20x (Enterprise Value 5.90b / FCF TTM 1.13b)
FCF Yield = 19.21% (FCF TTM 1.13b / Enterprise Value 5.90b)
FCF Margin = 20.98% (FCF TTM 1.13b / Revenue TTM 5.40b)
Net Margin = 8.41% (Net Income TTM 454.2m / Revenue TTM 5.40b)
Gross Margin = 41.56% ((Revenue TTM 5.40b - Cost of Revenue TTM 3.16b) / Revenue TTM)
Gross Margin QoQ = 39.65% (prev none%)
Tobins Q-Ratio = 0.39 (Enterprise Value 5.90b / Total Assets 15.3b)
Interest Expense / Debt = 5.85% (Interest Expense 52.9m / Debt 904.3m)
Taxrate = 21.00% (120.7m / 574.9m)
NOPAT = 448.7m (EBIT 567.9m * (1 - 21.00%))
Current Ratio = 1.35 (Total Current Assets 3.86b / Total Current Liabilities 2.87b)
Debt / Equity = 0.25 (Debt 904.3m / totalStockholderEquity, last quarter 3.59b)
Debt / EBITDA = -0.11 (Net Debt -95.0m / EBITDA 846.6m)
Debt / FCF = -0.08 (Net Debt -95.0m / FCF TTM 1.13b)
Total Stockholder Equity = 3.51b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 454.2m / Total Assets 15.3b)
RoE = 12.93% (Net Income TTM 454.2m / Total Stockholder Equity 3.51b)
RoCE = 12.87% (EBIT 567.9m / Capital Employed (Equity 3.51b + L.T.Debt 898.5m))
RoIC = 3.68% (NOPAT 448.7m / Invested Capital 12.2b)
WACC = 6.70% (E(6.00b)/V(6.90b) * Re(7.01%) + D(904.3m)/V(6.90b) * Rd(5.85%) * (1-Tc(0.21)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.18 | Cagr: -0.37%
[DCF] Terminal Value 74.28% ; FCFF base≈1.17b ; Y1≈1.10b ; Y5≈1.01b
[DCF] Fair Price = 269.0 (EV 16.0b - Net Debt -95.0m = Equity 16.1b / Shares 59.9m; r=8.35% [WACC [floored]]; 5y FCF grow -7.97% → 2.50% )
EPS Correlation: 34.96 | EPS CAGR: 11.99% | SUE: -0.15 | # QB: 0
Revenue Correlation: 99.02 | Revenue CAGR: 12.76% | SUE: -0.84 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.64 | Chg30d=-1.61% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.82 | Chg30d=-1.09% | Revisions=-44% | Analysts=8
EPS current Year (2026-12-31): EPS=7.87 | Chg30d=-0.43% | Revisions=-44% | GrowthEPS=+6.6% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=8.86 | Chg30d=+0.18% | Revisions=+18% | GrowthEPS=+12.6% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: -21% (up=10, down=16)